Ackman backs Valeant CEO as shares tumble to 2-1/2 year lows
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- S&P 500, Nasdaq drop as tech megacap declines outweigh upbeat Micron forecast
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Valeant (VRX) Price Target Cut to $195 at Guggenheim; Thesis Intact
November 6, 2015 6:29 AM ESTGuggenheim analyst Louise Chen lowered her price target on Valeant Pharmaceuticals (NYSE: VRX) to $195.00 (from $300.00) but maintained a Buy rating saying the investment thesis remains intact.
Chen commented, "We are lowering our PT for VRX to $195 from $300. The decrease in our PT is... More
Worst Case Valeant (VRX) is a Buy - Mizuho
November 5, 2015 3:13 PM ESTMizuho Securities analyst Irina Koffler said worse case analysis and Valeant Pharmaceuticals (NYSE: VRX) is a Buy. The firm reiterated a Buy rating and $155 price target.
The stock is no longer trading on fundamentals in our view. We look at a liquidation valuation in the extreme case that management is ousted and the business is put up for sale under distressed conditions. We conclude shares are undervalued and reiterate our BUY rating
Key points:
We try to remain rational and reiterate our BUY rating: We understand the... MoreHedgEye says Valeant Pharma (VRX) may fall another 75%
November 5, 2015 1:14 PM ESTHedgEye says Valeant Pharma (NYSE: VRX) may fall another 75%
... MoreThree Reasons Valeant (VRX) is Plunging Today
November 5, 2015 12:02 PM ESTInvestors continue to scratch their head as to why Valeant Pharma (NYSE: VRX) plunged 20% today. There are three theories to explain today's wild ride. The first theory is that there was... More
BMO Capital Sees Valeant (VRX) Weakness Related to Ackman Comments that Pearson Might Have to Go
November 5, 2015 11:47 AM ESTBMO Capital analyst Alex Arfaei weighed in on today's weakness in Valeant Pharmaceuticals (NYSE: VRX), saying they suspect that the decline is primarily related to Mr. Ackmans comments published today in the Wall Street Journal suggesting that Valeants CEO, Mr. Pearson, might have to go.
The article discloses conversations between Mr. Ackman and Valeants lead director, Robert Ingram. According to the article, Mr. Ackman told Mr. Ingram "If Mike [Pearson] hides in the bunker on this, he cant be CEO." Moreover, according to the article, Mr. Ackman told Mr.... More
